<DOC>
	<DOCNO>NCT02412111</DOCNO>
	<brief_summary>This Phase 3 , randomize , double-blind , ivacaftor-controlled , parallel-group , multicenter study subject age 12 year old CF heterozygous F508del-CFTR mutation second CFTR allele gate defect clinically demonstrated ivacaftor responsive .</brief_summary>
	<brief_title>A Phase 3 Study VX-661 Combination With Ivacaftor Subjects Aged 12 Years Older With Cystic Fibrosis , Who Have One F508del-CFTR Mutation Second Mutation That Has Been Demonstrated Clinically Responsive Ivacaftor</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Heterozygous F508delCFTR mutation second CFTR allele gate defect clinically demonstrated ivacaftor responsive FEV1 ≥40 % ≤90 % predict normal age , sex , height screen Stable CF disease judge investigator . History comorbidity , opinion investigator , might confound result study pose additional risk administer study drug subject . Pregnant nursing female ( female childbearing potential must negative pregnancy test Screening Week 4 Visits ) . Sexually active subject reproductive potential willing follow contraception requirement</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>